Role of Vitamin D as an Adjuvant to Oral Hypoglycemic Drugs in Treatment of Type-2 Diabetic Patients
DOI:
https://doi.org/10.3126/ajms.v11i2.26924Keywords:
Diabetes Mellitus Type 2, Glycemic control, Vitamin DAbstract
Background: Type 2 diabetes mellitus (T2DM) is considered as one of the nonskeletal diseases related with deficiency of vitamin D. Both T2DM and vitamin D deficiency have similar risk factors, such as obesity, aging, and sedentary lifestyle. Cardiovascular diseases (CVDs) and metabolic syndrome disorders are also associated with vitamin D deficiency. Vitamin D plays an important functional role in glucose homeostasis through its effects on insulin secretion and sensitivity. It may reduce insulin resistance (IR) indirectly through its effect on calcium and phosphate metabolism and through upregulation of the insulin receptor gene. Thus, this study was designed to evaluate role of vitamin D as an adjuvant to oral hypoglycemic drugs in treatment of Type 2 diabetic patients.
Aims and Objectives : Vitamin D deficiency appears to be related to the development of diabetes mellitus type 2 and the metabolic syndrome. Vitamin D may affect glucose homeostasis, vitamin D levels having been found to be inversely related to glycosylated hemoglobin levels in diabetes mellitus. The aim of the study was to evaluate role of vitamin D as an adjuvant to oral hypoglycemic drugs in treatment of Type 2 diabetic patients.
Materials and Methods: The study was done on 60 patients diagnosed with T2DM. A total of 60 patients, control group were type 2 Diabetic patients on oral hypoglycemic drugs without vitamin D supplementation (n=30) and study group was type 2 Diabetic patients on oral hypoglycemic drugs with vitamin D supplementation (n=30).
Results: The mean aged of patients was 43.27±8.80 in control group and 47.93±8.39 in study group. The family history of diabetes mellitus was 39 patients. HbA1C, FBG, Postprandial were decreased in study group as compared to control group from baseline (0 day) to 90 days, respectively. Other parameters like hemoglobin, Serum Creatinine serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase were slight changes in study group as compared to control group from baseline (0 day) to 90 days, respectively.
Conclusion: The present study demonstrated that vitamin D as an adjuvant to oral hypoglycemic drugs in treatment in diabetic patients, vitamin D levels being related to glycemic control in diabetes mellitus type 2. These findings may have therapeutic implications as cautious vitamin D supplementation may improve glycemic control in diabetes mellitus type 2.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
